1. In vitro activity of the αvβ3 integrin antagonist RGDechi-hCit on malignant melanoma cells
- Author
-
Marina, Pisano, Ivan, DE Paola, Valentina, Nieddu, Ilaria, Sassu, Sara, Cossu, Grazia, Galleri, Annarita, Del Gatto, Mario, Budroni, Antonio, Cossu, Michele, Saviano, Giuseppe, Palmieri, Laura, Zaccaro, and Carla, Rozzo
- Subjects
Cell Movement ,Cell Line, Tumor ,Cell Adhesion ,Humans ,Angiogenesis Inhibitors ,Integrin alphaVbeta3 ,Peptides ,Melanoma - Abstract
In malignant melanoma (MM), overexpression of αvβ3 integrin is linked to a more metastatic phenotype. Development of anti-αvβ3 agents able to counteract melanoma progression would be helpful for disease treatment. A new selective ligand of αvβ3, RGDechi-hCit, has anti-angiogenic properties against endothelial cells in animal angiogenesis models. The aim of this study was to evaluate the in vitro effects of the RGDechi-hCit peptide on MM cell lines.Cytofluorimetric analysis characterized the cell surface expression of αvβ3 integrin on seven MM cell lines: A375, WM266-4, SK-Mel-28, Sbcl2, LB24Dagi, PR-Mel and PNP-Mel. Cell proliferation, adhesion, and migration assays were carried out using the αvβ3-antagonist RGDechi-hCit.Proliferation was not significantly inhibited by RGDechi-hCit, although striking morphological changes were detected in MM cell lines highly expressing αvβ3. Conversely, assays on fibronectin-coated plates showed a significant RGDechi-hCit dose-dependent inhibitory effect on both adhesion and migration.The data demonstrate anti-adhesion and anti-migration, but not antiproliferative, activities of RGDechi-hCit against MM cells.
- Published
- 2013